Evaluation of intermediate coronary stenoses in acute coronary syndromes using pressure guidewire

Giampaolo Niccoli,1 Ciro Indolfi,2 Justin E Davies3

ABSTRACT

Fractional flow reserve (FFR) is increasingly used to guide myocardial revascularisation. However, supporting evidence regarding its use originates from studies that have enrolled mainly patients with stable angina, while patients with acute coronary syndromes (ACS) have not been included. Notably, multifactorial microvascular dysfunction and an increased sympathetic tone in patients with ACS may lead to blunted response to adenosine and false-negative results of FFR due to submaximal hyperaemia. This may raise the possibility of deferring treatment of stenosis that instead would have needed dilatation, thus leaving a residual risk of preventable cardiac events. In this literature review, we aim at summarising laboratory and clinical investigations concerning the use of FFR in culprit and non-culprit lesions in ACS. Furthermore, we will report recent data on instantaneous wave-free ratio, an adenosine-free index of functional stenosis severity, in stable coronary artery disease and in patients with ACS.

INTRODUCTION

Invasive functional evaluation of intermediate coronary stenosis, stenosis determining a luminal diameter narrowing of ≥40% but ≤70%, is increasingly used for decision making in patients with coronary artery disease (CAD).1 Fractional flow reserve (FFR) has been reported to identify ischaemia-producing lesions with high accuracy.1 The latest (2014) European Society of Cardiology (ESC) guidelines on myocardial revascularisation suggest that, when non-invasive stress imaging is contraindicated, non-diagnostic or unavailable, the measurement of FFR is recommended during diagnostic coronary angiography.2 Deferral of percutaneous coronary intervention (PCI) or coronary artery bypass graft in patients with FFR >0.80 appears safe.2 However, this evidence originates from studies that have enrolled mainly patients with stable angina (SA)3 4 and data about the role of FFR guidance in patients with acute coronary syndromes (ACS) are limited.

Of note, an essential prerequisite for FFR calculation is the achievement of “maximal” hyperaemia, usually accomplished by adenosine administration.1 Patients with ACS may however have mechanisms leading to blunted response to adenosine and submaximal hyperaemia (figure 1). Thus, normal FFR value (>0.80) may indeed be falsely negative due to incomplete hyperaemia. This phenomenon may be true for both culprit and non-culprit lesions in ACS and is dependent on raised microvascular resistance and reduced coronary flow reserve (CFR) as recently summarised by Echavarria-Pinto et al.5 Importantly, the possibility of false-negative results of FFR is increased around the grey zone of FFR and values of FFR between 0.81 and 0.85 should be managed cautiously as a residual risk of events may be present.6

The goal of this literature review is to summarise laboratory and recent clinical investigations concerning the use of FFR in culprit and non-culprit lesions in ACS mainly because these studies carry important implications both for treatment and prognosis. Particular emphasis will be placed on the potential current data on the use, and potential limitations of FFR in routine clinical practice for assessment of patients with ACS. Finally, recent data on instantaneous wave-free ratio (iFR), an adenosine-free index of functional stenosis severity, will be reviewed in detail, particularly for the possibility to assess the functional relevance of coronary stenosis without the need of adenosine administration.

CURRENT CLINICAL EVIDENCE ON FFR IN ACS

Culprit lesions in ST-elevation myocardial infarction

Although the feasibility of making measurements was recently evaluated, no data have been published to show an improvement of clinical outcome when using FFR of the culprit lesion in the acute phase of the ST-elevation myocardial infarction (STEMI), thus currently it is not indicated.7 Of note, the percentage of intermediate coronary stenosis...
in culprit vessels of patients with STEMI accounts for less than 10%.8 FFR could be indicated later after a successful thrombolysis. However, it is still unknown how long it takes for microvascular stunning following an acute coronary episode to resolve. In fact, the time to recovery of the microvasculature is variable, depending on the size of infarction, and the occurrence of microvascular obstruction (MVO). The longevity of MVO can be as short as days, and as long as a week, or more.7 9 The variable degree of reversible microvascular stunning reduces the maximal achievable flow resulting in smaller pressure gradients and their associated higher FFR values.1–7 9–11 This phenomenon increases the chance of a false-negative FFR measurement. However, due to the phenomena described above, any physiological index may be questionable for the evaluation of the culprit vessel. Conversely, low FFR values should be considered reliable. Small studies have suggested that FFR assessment is more reliable between 4 and 6 days following the index event,12–14 as soon as the microcirculation can dilate sufficiently to enable maximal hyperaemia.

Non-culprit lesions in STEMI

A substantial percentage (30%–50%) of patients with STEMI have multivessel coronary disease (MVD). These patients are a subgroup at high risk for major adverse cardiac events (MACE) in the first year after primary PCI for STEMI.10

Since intermediate stenosis rate in non-culprit vessels of STEMI accounts for about 70%, the evaluation of non-culprit lesions represents an important clinical issue.13 Of note, in this setting of patients, a coronary and peripheral vasoconstriction due to alpha-adrenergic stimulation may occur and even angioplasty could induce a subsequent vasoconstriction.16 Therefore, how and when to interrogate a non-culprit intermediate stenosis is still unknown. The first question is the reliability of FFR of non-culprit lesions in the acute phase of STEMI. Italianis et al. reported the reproducibility of FFR measurements in 101 patients undergoing PCI for acute myocardial infarction (MI) (75 STEMI and 26 non-ST-elevation myocardial infarction (NSTEMI)).15 FFR measurements were originally made in the non-culprit lesions at the time of culprit vessel PCI and then repeated 35±4 days later. In a subgroup of 14 patients, the index of microvascular resistance (IMR) was also measured at the time of culprit vessel PCI and repeated 35±4 days later.13 Although the mean value of FFR of non-culprit coronary artery stenoses during the acute phase and at follow-up was not statistically different, some FFR values crossed important clinical cut-off points (around 10% of patients). Of note, the recent DANAMI-3-PRIMULTI study showed that the complete revascularisation using FFR-guided PCI in patients with STEMI and MVD reduced the risk of future events at a median follow-up of 27 months, compared with no further invasive intervention after primary PCI.17 However, many issues remain open. First of all, since the FFR measurements were done at a median of 2 days after the initial PCI procedure, the study might be affected by disturbances in microvascular function and oedema in the area. Second, the rate of events at follow-up in deferred lesions by FFR is not reported, thus not allowing again the assessment of residual risk carried by FFR guidance in ACS.

FFR in NSTEMI

Two clinical studies have assessed the impact of the use of FFR in NSTEMI. The first clinical study was FAME which included 328 patients with ACS out of a total of 1005 patients with MVD.18 Patients were enrolled with unstable angina (UA) or NSTEMI with positive troponin but total creatine kinase <1000 U/L. FFR guidance was associated with a 5.1% absolute and a 3.7% relative risk reduction after 2 years (combined end point of death, MI or revascularisation), similar to that obtained in the remainder of the patients with stable CAD. This ACS substudy was a subgroup analysis which was not powered to detect superiority of FFR in non-culprit ACS. Furthermore, theoretical limitation surrounds the time of FFR interrogation (within 5 days of admission but the exact time is not reported) that may affect FFR results due to the evolving status of the coronary microcirculation. Finally, neither the actual lesion assessed (culprit vs non-culprit) nor the event rate in deferred lesions by FFR in FAME is reported.

The second clinical study, FAMOUS-NSTEMI trial,10 randomised 350 patients with NSTEMI with at least one coronary stenosis of ≥30% severity by visual assessment of either FFR-guided versus angiography-only approach. The reported percentage of intermediate lesions was 25%. The study showed an increased proportion of patients treated initially by medical therapy in the FFR-guided group when compared with the angiography-guided group (22.7% vs 13.2%), this is despite 1MACE in both groups being similar (figure 2). The median time from the index episode of myocardial ischaemia to angiography was 3 days. A trend for more periprocedural MI in angiography-guided procedure and for more MACE in the FFR guided-procedure was observed. Interestingly, MACE rate was 7.5% in deferred patients by FFR and 0% in deferred patients by angiography.
myocardial ischaemia. In particular, a reduction of baseline flow severe enough to impair regional wall motion in remote, normally contracting myocardium subtended by angiographically normal coronary arteries has been observed very early after the infarction. Both coronary microvascular dysfunction and the impairment of regional wall motion are relieved by alpha-blockers, thus suggesting that enhanced sympathetic activation is likely to contribute to these abnormal findings. Myocardial ischaemia reflexively increases cardiac sympathetic nerve activity by stimulating cardiac ventricular and coronary nerve-ending receptors.

On the other hand, in patients with STEMI, coronary microvascular dysfunction in the territory of a recanalised infarct-related artery is responsible for the MVO, which may lead to lack of perfusion of the myocardium despite the opening of the infarct-related artery. Of note, this phenomenon has been described for STEMI but also for NSTEMI due to embolisation of active plaque material or thrombotic material.

Bax et al. assessed CFR and minimal microvascular resistance by combined pressure-flow wires in the culprit vessel of patients with acute MI immediately after reperfusion, then at 1 week and 6 months. CFR increased while minimal microvascular resistance decreased at follow-up in the infarct-related artery. In a recent study, CFR, IMR and FFR were assessed in the culprit lesion at the time of primary PCI, and 6 months later the authors showed that FFR significantly reduced between the acute phase and follow-up reflecting an increase in coronary flow with recovery of the coronary microcirculation. Uniquely, the authors demonstrated a link between IMR and extent of MVO extent on cardiac MRI. Similar findings were found when flow was assessed by angiography (thrombolysis in myocardial infarction (TIMI) flow grading) as patients with TIMI 2 flow had higher FFR values than those with final TIMI 3 flow in the infarct-related artery. These studies suggest that FFR assessment of culprit lesion in STEMI may lead to false-negative results during the acute phase.

Nevertheless, prior studies showed a concordance of single-photon emission computed tomography (SPECT) and FFR in the assessment of culprit lesions in MI (both STEMI and NSTEMI) ranging from 71% to 85%. However, the variable time from ischaemic event to FFR (from 2 days to 6 days), the small sample size of the studies and the inclusion of heterogeneous patient subset (STEMI non-reperfused by primary PCI rarely encountered nowadays, NSTEMI studies by angiography >24 hours from chest pain onset not currently recommended by guidelines) do not allow the drawing of a firm conclusion on the accuracy of FFR in the acute setting when the infarct-related artery is interrogated. Finally, non-culprit lesions were not included in such studies, thus data were not provided on the correlation between non-invasive ischaemia and FFR similarly to that available in patients with SA in many studies of FFR validation.

**Figure 2** Kaplan-Meier plots of cumulative event rate in patients with acute coronary syndromes enrolled in the FAMOUS-NSTEMI study according to FFR or angio-guidance. FFR, fractional flow reserve. (Adapted from Tamita et al.)

**POTENTIAL LIMITATIONS OF FFR IN ACS**

A prerequisite of FFR formula calculation is the achievement of so-called ‘maximal’ hyperaemia due to dilatation of the microcirculation following either intracoronary or intravenous adenosine administration. However, coronary microvascular dysfunction may hamper the response to vasodilators in ACS due to both pre-existing dysfunction or damage to the microcirculation related to ACS. In this context, there is much evidence to support the notion that in patients with ACS, coronary endothelial dysfunction may pre-exist to the acute coronary event and might even contribute to its pathogenesis. In particular, reports indicate that abnormal non-endothelium-dependent microvascular dilatation appears to be involved in functional and structural alterations that lead to impaired CFR with ageing, hypertension, diabetes, dyslipidaemia, insulin resistance and chronic inflammatory diseases.

Moreover, there is a growing body of evidence to suggest that the presence of endothelial dysfunction is an independent predictor of cardiovascular (CV) events. Furthermore, in patients with NSTEMI, the coronary microvascular dysfunction distal to the critical stenosis plays an important role in determining the severity of
Although the culprit lesion is often clear in STEMI, not necessitating functional evaluation, the identification of the culprit lesion may be more difficult in NSTEMI where patients often present with MVD. Of note, a recent study by Layland et al \(^{29}\) failed to show differences in resistive reserve ratio, a measure of the vasodilatory capacity of the microcirculation, in culprit lesions of NSTEMI versus that of SA patients. In this study, IMR tended to be higher (although not statistically different) in culprit vessels of NSTEMI versus that of SA. Again, as in previous studies, IMR was much higher in culprit lesions of STEMI and FFR was also higher as compared with NSTEMI and SA. Importantly, the resistive reserve ratio was negatively correlated with baseline troponin and pre-PCI IMR and tended to be lower (2.46 vs 2.8) in patients with NSTEMI versus those with SA, suggesting that the vasodilatory capacity of the microcirculation may be preserved in some but not all patients with ACS. Finally, the authors assessed these invasive indexes at a mean time of 4 days while currently most patients with ACS and diagnoses of NSTEMI are evaluated within 24 hours from admission—a time frame in which the microcirculation may be more dysfunctional. Thus, the role of FFR in the culprit vessel of NSTEMI needs further studies addressing the effect of time on the assessment of functional indexes of stenosis evaluation.

In non-culprit lesions, although one study reported little change in FFR during the acute phase and follow-up as discussed above,\(^{10}\) in the assessment of non-culprit lesions in STEMI other studies have provided conflicting results. Accordingly, lesion severity by angiography has been shown to be exaggerated in non-culprit lesion during the acute phase in ACS in one study,\(^{30}\) and hyperaemic microvascular resistance (HMR) was shown to be higher at the time of revascularisation in another study while it was reduced after 6 months both in the infarct and non-infarct-related arteries.\(^{31}\) Furthermore, a significant decrease in FFR was shown in a study evaluating non-culprit lesion of STEMI during the acute phase and after a mean of 42±10 days (0.84±0.08 vs 0.82±0.08, p=0.025).\(^{31}\) Finally, discordance between FFR and hyperaemic stenosis resistance (HSR) has been recently suggested by a study comparing FFR and HSR in non-culprit lesions of NSTEMI versus SA.\(^{32}\) Discordance was more common in ACS than SA and was related to the variation in microvascular resistance between baseline and hyperaemia (less variation related to more discordancy) (figure 3) and the baseline inflammatory status as assessed by C-reactive protein (CRP) (higher levels related to more discordancy, a finding to be taken into account as CRP may be elevated in as many as 50% of patients with ACS). As a previous study showed that HSR is a better index of ischaemia than FFR,\(^{33}\) these data could suggest that FFR may fail to identify ischaemic lesions in a subset of patients with ACS in non-culprit lesions. Such findings are not surprising as dissociation between FFR and CFR has been previously demonstrated using combined evaluation of microvascular resistances, CFR and FFR in patients with SA and UA.\(^{5,34}\) Such discordance has been suggested to be due to clinically relevant coronary pathophysiology.\(^{35}\) In particular, the variability of the microcirculation and flow across the stenosis due to the biologic variability of the stenosis in patients with ACS is therefore to be anticipated. There are several possible mechanisms which may explain this phenomenon in patients with ACS. First, increased release of vasoconstrictors has been demonstrated previously in ACS. Accordingly, Heusch\(^{36}\) showed that adenosine is not able to eliminate \(\alpha\)-adrenergic and endothelin-mediated coronary vasoconstriction, and possibly vasoconstriction induced by other powerful mediators such as angiotensin, serotonin and thromboxane A2. Second, non-culprit plaque in ACS may have vulnerable features and may also be associated with plaque rupture and distal embolisation that hamper the response of the microvessels to vasodilators.\(^{37}\) Moreover, a study by Tomai et al found that in the presence of elevated CRP, patients with NSTEMI showed a reduced response to substance P.\(^{38}\) This elevated level of CRP suggests the presence of endothelial dysfunction. Furthermore, CRP levels have been associated with levels of vasoconstrictors and structural alterations of the microcirculation in cases of systemic inflammatory activation.\(^{19}\) Again, the effects of elevation of left ventricular (LV) end-diastolic pressure should not be underestimated, and may cause a significant underestimation of lesion severity by FFR. This is particularly prominent in the acute phase.\(^{39}\) Finally, in the case of plaque rupture, the severity of stenosis of the acute coronary lesion may fluctuate due to thrombus incorporation in the lesion or vessel remodelling.

In order to try and overcome the resistance to the use of vasodilators in patients with ACS, much attention is paid to the route and dosage of hyperaemic agents such as adenosine.\(^{1}\) Under such circumstances, the usual dosing of adenosine may be insufficient to achieve maximal hyperaemia. To overcome this problem, some studies have suggested that, by increasing the adenosine dosage (up to 600 mcg), FFR may be of benefit.\(^{30,41}\) However, these protocols have been employed only in patients

---

**Figure 3** Variation of microvascular resistance in patients with stable angina or non-ST elevation acute coronary syndrome (NST-ACS). (Adapted from Sels et al.\(^{18}\))
with stable CAD, and therefore cannot be recommended in ACS. Of note, if escalation of adenosine dosing may increase hyperaemia, it carries a greater risk, particularly in the unstable setting of further antagonism of unstable haemodynamics. In such scenarios, high-dose intravenous administration of adenosine may lead to false-positive FFR results in addition to an acute and undesirable deterioration in haemodynamics.42 When making an assessment in the acute setting, the potential for such undesirable deterioration should always be considered, especially when there is a large myocardial mass and depressed LV function is involved.

**OTHER FUNCTIONAL INDEXES TO ASSESS CORONARY STENOSIS IN ACS**

Based on the considerations stated above, the search for the best index of functional stenosis severity evaluation in ACS is still ongoing. Table 1 reports all the functional parameters tested in patients with ACS. Two approaches need to be evaluated in ACS: the use of pressure-flow wires that allow the combined assessment of stenosis and microvascular resistance alongside FFR, and newer pressure-only adenosine-free indexes such as iFR. However, the impact of microvascular dysfunction and plaque activity on such indexes should be a matter of future studies. Of note, iFR has recently been suggested to have better correlation with CFR than FFR.43 Interestingly, the closer relationship between iFR and CFR is lost when iFR is measured during adenosine administration, suggesting that the hyperaemic response itself is the most likely cause of conflicts between pressure indexes and CFR.

### HSR index

HSR is calculated by combined pressure-flow assessment of coronary stenosis severity.44 It is calculated by dividing the trans-stenotic pressure gradient by mean flow under...
hypoaemic conditions. HSR is less dependent than FFR on microvascular function, and it has been shown to be superior to FFR for ischaemia detection by myocardial perfusion imaging in patients with SA. Pressure-flow wires can be used to calculate the HMR, defined as the ratio of mean distal pressure divided by mean distal flow under hyperaemic conditions. Myocardial resistance has an important effect on any physiological index such as FFR. This is because the relationship between FFR and HSR is modulated by the magnitude of HMR, such that for any given level of epicardial disease, equivalent FFR severity increases with increasing resistance. As HSR is less susceptible to resistance changes than FFR, it may be superior in detecting ischaemia-producing lesions in acute patients. To date, a direct comparison between FFR and HSR in ACS patient populations remains lacking.

**iFR for evaluation of stenosis severity in stable patients and patients with ACS**

Despite the strong evidence base for FFR, the current use of FFR in patients with ACS remains rather low worldwide. Reasons for this are multifactorial, including: lack of sufficient device reimbursement, increased procedural time and costs for adenosine administration, contraindication in patients with asthma and chronic obstructive pulmonary disease, and residual reliance on visual assessment of coronary angiography. An alternative adenosine-free index of coronary stenosis, iFR, was recently introduced in patients with stable coronary disease to assess the stenosis severity. In particular, iFR, a pressure-only index, has been evaluated in large registries in real life, showing good agreement with FFR and at least similar discriminative power for ischaemia detection when compared with FFR. Of note, iFR, when compared with FFR, shows stronger correlation and better agreement with CFR, suggesting that iFR may be better suited for stenosis severity evaluation in cases of dissociation between FFR and CFR, a potential situation in ACS (figure 4). Interestingly, iFR/FFR correlation shows no difference between patients with ACS and stable patients in a recent study. The Forecast Trial was the first study that evaluated the iFR for the assessment of non-culprit intermediate stenoses in patients with ACS, and its classification match to FFR in such a clinical context is not inferior compared with stable CAD. However, it has to be stated, although there is a good classification match between the two indexes, it does not achieve complete agreement. In particular, as a resting measure, iFR is more consistent across microvascular and non-microvascular dysfunction analysis (area under the curve: 0.87). In addition, neither the localisation of the stenosis within the coronary tree (p=0.147) nor the time interval from the acute event (p=0.550) significantly influenced the concordance of iFR with FFR. Therefore, the iFR, during the wave-free period and without hyperaemic stimulation, is feasible in patients with ACS. Indeed, it is a promising diagnostic technique for the evaluation of non-culprit intermediate stenoses in patients with ACS, and its classification match to FFR in such a clinical context is not inferior compared with stable CAD. However, it has to be stated, although there is a good classification match between the two indexes, it does not achieve complete agreement. In particular, as a resting measure, iFR is more consistent across microvascular and non-microvascular dysfunction.
states. Importantly, ischaemic FFR values (≤0.75) may be generated by high hyperaemic flow rates and higher-than-average CFR. Specifically, the generation of large hyperaemic gradients in stenoses with normal iFR values (>0.9) identifies a particular subgroup of patients with high CFR. These lesions demonstrate, on average, magnitudes of hyperaemic flow velocities equal to what is observed in stenoses with FFR >0.80, both significantly higher than flow velocities seen in the overall population of FFR-significant lesions (≤0.75). Conversely, an increase in microvascular resistance due to microvascular disease or submaximal hyperaemia will be reflected in an increase in distal coronary pressure, and thus in an increase in FFR, while the hampered flow through the stenosis will result in a decrease in CFR, and vice versa. In this context, the IFR could be helpful to avoid the false-negative FFR values in ACS, as slightly more patients are ‘positive’ with iFR with microcirculatory disease. This phenomenon depends on the population under study and is more pronounced in microvascular dysfunction state such as ACS. Thus, taken together, these data are supportive of the potential future role of iFR as a tool to guide decision making in ACS. While the current data provide an interesting background to the relationship between non-hyperaemic and hyperaemic indices, prior to the results of large randomised clinical trials, it is not possible to know whether iFR is superior to FFR in the evaluation of coronary stenoses in patient with ACS. Two large prospective randomised clinical trials, FLAIR (NCT02053038) and SWEDEHEART (NCT02166736), will further address the use of iFR and FFR in the diagnostic evaluation of stenosis severity for the assessment of intermediate stable coronary stenoses, and non-culprit stenoses in ACS. Patients will be recruited from standard clinical work flows, and it is anticipated that up to 50% of patients evaluated will be in the ACS arm. Moreover, the FLAIR study will look at MACE, and cost-effectiveness at 1 year using established iFR and FFR dichotomous cut-off points.

CLINICAL IMPLICATION OF DEFERRING CORONARY STENOSIS TREATMENT IN ACS VERSUS SA

In the DEFER trial,3 deferral of patients with stable CAD and FFR <0.75 was associated with a very low event rate (around 3%) after 5 years. Based on this study and others, FFR has attained a class IA level of recommendation in the latest ESC guidelines on myocardial revascularisation.5 Most of the evidence is gained from patients with stable CAD with few little data from patients at higher risk of events associated with deferral of treatment in ACS. Notably, a recent study has suggested that FFR has a continuous and independent relationship with subsequent outcomes, suggesting that borderline FFR value may still benefit from revascularisation,48 while another study has suggested accordingly that the risk of deferred lesion intervention may be modulated by clinical factors as well as FFR values.50 Lopez-Palop et al51 showed a similar event rate in non-culprit lesion assessed by FFR (with a 0.75 cut-off) when comparing treated versus deferred lesions (7.4% vs 7.7%), an event rate higher than that observed after 1 year in the DEFER study. Similarly, Fischer et al52 showed that, by using a 0.75 cut-off, deferred lesions in non-culprit vessels of ACS versus those with no ACS had a trend for higher event rate (28% vs 17%). Finally, in an all-comers ACS population (NSTEMI and STEMI >24 hours) deferring treatment with a cut-off of 0.75 was associated with an event rate related to the deferred lesion of 7.5%.53 These studies suggest that the risk associated with deferring lesions in non-culprit territories of ACS is higher than that expected for deferred SA lesions based on FFR.

However, the natural history of the coronary lesions of patients with ACS is different from its stable counterpart. Moreover, compared with patients with single vessel disease, individuals with ACS and MVD presented a poorer outcome. It is still unclear if this phenomenon is attributable to an increased disease burden and activity or because ischaemia-producing lesions in other territories are left untreated.54 Some studies have suggested that patients with MI and MVD have a considerable proportion of unstable and vulnerable lesions in addition to the identified culprit artery.55 Thus, the importance of FFR assessment could be less pronounced, as the likelihood of vulnerable plaque rupture is not strictly related to FFR, but to the underlying activity of the disease. Indeed, the plaque instability independent of the stenosis severity itself may be driver of the events in the ACS. It means that FFR may be inaccurate in predicting the risk of future events when their values are negative and when they are positive.

Finally, a recent study5 on a mixed population of patients with SA and ACS showed that in borderline values of FFR (between 0.8 and 0.85) the risk of events is particularly high (HR 1.63, 95% CI 1.14 to 2.33). The data presented are not surprising as some deferred lesion, especially those in the borderline zone, may represent false-negative results of FFR due to high HMR and low CFR. Of note, HMR is associated with ischaemia independently of FFR,56 while an abnormal CFR with a normal FFR is associated with a worse prognosis after 10 years of follow-up in the case of stable patients.27 These observations are probably related to the strong prognostic role of coronary microvascular dysfunction in addition to that conferred by stenosis severity, as clearly suggested by studies using positron emission tomography.57,58

FUTURE PERSPECTIVES AND CONCLUSIONS

Patients with ACS represent a different subset of CAD characterised often by microvascular dysfunction and transient coronary vasoconstriction that may affect FFR results. This notion should be taken into account as deferring lesion with high FFR values especially in the borderline zone which may lead to recurrent events. Whether this is due to undertreatment of severe stenosis
or to worse microvascular function has not been tested to date. However, other indexes of functional stenosis evaluation with better correlation with microvascular function may possibly be superior to FFR. At present, physicians should remain vigilant that borderline FFR values in patients with ACS may be underestimates of true severity stenosis.

Contributors All the authors: 1) provided substantial contributions to the conception or design of the work, or the acquisition, analysis or interpretation of data; 2) drafted the work and revised it critically for important intellectual content; 3) approved the version published.

Competing interests None declared.

Open Access This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ © Article author(s) (or their employer(s) unless otherwise stated in the text of the article) 2017. All rights reserved. No commercial use is permitted unless otherwise expressly granted.

REFERENCES


